Biopharmaceutical Excipient Manufacturing Market by Type of Biologics (Antibodies, Vaccines, Cell Therapies and Other Biologics), Type of Excipient (Carbohydrates, Polymers, Solubilizers / Surfactants, Polyols, Proteins / Amino Acids and Others, Company Size (Small, Mid-sized, Large / Very Large), Scale of Operation (Preclinical, Clinical and Commercial) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2022

  • Pages
    175

  • View Count
    3185

Example Insights

Biopharmaceutical-Excipient-Manufacturing-Market-Context Biopharmaceutical-Excipient-Manufacturing-Market-List-of-Biopharmaceutical-Excipient-Manufacturers Biopharmaceutical-Excipient-Manufacturing-Market-Distribution-by-Location-of-Headquarters Biopharmaceutical-Excipient-Manufacturing-Market-Distribution-by-Type-of-Formulation
Biopharmaceutical-Excipient-Manufacturing-Market-Company-Competitiveness-Analysis Biopharmaceutical-Excipient-Manufacturing-Market-Partnerships-and-Collaborations Biopharmaceutical-Excipient-Manufacturing-Market-Recent-Expansions Biopharmaceutical-Excipient-Manufacturing-Market-Capacity-Analysis
Biopharmaceutical-Excipient-Manufacturing-Market-Likely-Growth-Scenarios Biopharmaceutical-Excipient-Manufacturing-Market-Distribution-by-Region    

Overview

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide. Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. However, biological therapeutics are inherently less stable than small molecules and, hence, more prone to degradation by several physical and chemical degradation mechanisms. Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. Furthermore, excipients play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs). Additionally, biopharmaceutical excipients act as bulking agents, antioxidants or preservatives. As a result, the demand for biopharmaceutical excipients has grown considerably. However, for some of the biopharmaceutical excipients, such as lipids, the associated manufacturing processes are highly complex, capital-intensive and fraught with multiple challenges. Some of the major issues related to the production of GMP grade biopharmaceutical excipients include the need for specialized expertise, lack of facilities with the necessary infrastructure and capacity to produce the required quality of substances, as well as concerns related to storage, safety and efficacy. 

Considering the technical and routine operations-related challenges, an increasing number of biologics developers are increasingly relying on biopharmaceutical excipient manufacturers.  The benefits of engaging such third-party service providers are numerous; for instance, contracting a supplier for medical grade biopharmaceutical excipients enables sponsors to leverage specialty biopharmaceutical excipients (available with the manufacturers), access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers that claim to have the required capabilities to manufacture a variety of biopharmaceutical excipients, including lipids, lactose, trehalose, mannitol, succinate, Tween 20 and benzyl alcohol. These companies are increasingly focusing on the development of co-processed multifunctional biopharmaceutical excipients to improve the stability and effectiveness of novel biotherapeutics. It is worth highlighting that biopharmaceutical excipient manufacturers are actively trying to consolidate their presence in this field by entering into strategic alliances, enhance their respective manufacturing capabilities in order to meet the growing demand for excipients used in biologics. In fact, recently, a number of deals were inked between vaccine developers and biopharmaceutical excipient manufacturers in order to cater to the urgent need for lipids for the formers’ respective COVID-19 vaccines. With outsourcing being increasingly accepted as a viable and beneficial business model within this field, we anticipate the biopharmaceutical excipient manufacturing market to grow at a steady pace in the coming years.

Scope of the Report

The ‘Biopharmaceutical Excipient Manufacturing Market by Type of Biologics (Antibodies, Vaccines, Cell Therapies and Other Biologics), Type of Excipient (Carbohydrates, Polymers, Solubilizers / Surfactants, Polyols, Proteins / Amino Acids and Others, Company Size (Small, Mid-sized, Large / Very Large), Scale of Operation (Preclinical, Clinical and Commercial) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of companies engaged in manufacturing of biopharmaceutical excipients. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

  • A detailed assessment of the current landscape of engaged in offering biopharmaceutical excipients, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, location of manufacturing facilities, type of excipient (based on chemical composition (carbohydrates, polyols, polymers, proteins / amino acids, salts, lipids, and others), based on function (surfactants, stabilizers, tonicity modifiers, bulking agents, buffering agents, solubility enhancers, drug delivery system, chelators, antimicrobials, antioxidants and others), based on chemical structure (organic and inorganic)), scale of operation (preclinical, clinical and commercial),  type of formulation (liquid or parenteral and solid), type of biologic (vaccines, proteins / peptides, cell therapies, antibodies and blood products) and global regulatory compliance (United States Pharmacopoeia / United States Pharmacopoeia-National Formulary, European Pharmacopoeia, Japanese Pharmacopoeia, British Pharmacopoeia, China Pharmacopoeia, American Chemical Society grade, Indian Pharmacopoeia, Food Chemical Codex and Taiwan FDA).
  • An in-depth competitiveness analysis of the biopharmaceutical excipient manufacturers, based on supplier power (in terms of years of experience), company competitiveness (type of excipient based on chemical composition, function, chemical structure, and based on scale of operation, type of formulation, type of biologic, global regulatory compliance) and number of manufacturing facilities.
  • Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook. 
  • An analysis of recent partnerships inked between stakeholders engaged in this domain, during the period 2016-2021, covering distribution agreements, acquisitions, supply agreements, product development agreements, asset acquisitions, research and development agreements, manufacturing agreements, service alliances and other related agreements. 
  • A detailed analysis of the recent expansions undertaken by various biopharmaceutical excipient manufacturers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, type of excipient, type of drug molecule, most active players (in terms of number of recent expansions) and geographical distribution (region-wise and country-wise).
  • An estimate of the global installed capacity for biopharmaceutical excipients taking into consideration the capacities of various biopharmaceutical excipient manufacturers, along with information on the distribution of available global biopharmaceutical excipient production capacity based on several relevant parameters, such as company size (small, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial) and key geographical regions (North America, Europe, and Asia-Pacific).

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the biopharmaceutical excipient manufacturing market, over the next 15 years. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of biologics (antibodies, vaccines, cell therapies and other biologics), [B] type of excipient (carbohydrates, polymers, solubilizers / surfactants, polyols, proteins / amino acids and others), [C] company size (small, mid-sized, large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).  

In order to account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

Key Questions Answered

  • Who are the key players engaged in biopharmaceutical excipient manufacturing?
  • Which global regions are considered as key hubs for biopharmaceutical excipient manufacturing?
  • What type of partnership models are commonly adopted by stakeholders in this industry?
  • What kind of expansion initiatives have been undertaken by biopharmaceutical excipient manufacturers? 
  • What is current, global biopharmaceutical excipient manufacturing capacity of contract manufacturers?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the biopharmaceutical excipient manufacturing market in the short to mid-term, and long term.

Chapter 3 provides a general overview of the biopharmaceutical excipients. In addition, it includes information on their properties and classification, based on route of administration, chemical structure, function, ability to interfere with metabolization and efflux mechanisms. Further, it highlights various applications of biopharmaceutical excipients and their role in pharmaceutical and biopharmaceutical industry. 

Chapter 4 provides an overview of the current biopharmaceutical excipients, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, location of manufacturing facilities, type of excipient (based on chemical composition (carbohydrates, polyols, polymers, proteins / amino acids, salts, lipids, and others), based on function (surfactants, stabilizers, tonicity modifiers, bulking agents, buffering agents, solubility enhancers, drug delivery system, chelators, antimicrobials, antioxidants and others), based on chemical structure (organic and inorganic)), scale of operation (preclinical, clinical and commercial),  type of formulation (liquid or parenteral and solid), type of biologic (vaccines, proteins / peptides, cell therapies, antibodies and blood products) and global regulatory compliance (United States Pharmacopoeia / United States Pharmacopoeia-National Formulary, European Pharmacopoeia, Japanese Pharmacopoeia, British Pharmacopoeia, China Pharmacopoeia, American Chemical Society grade, Indian Pharmacopoeia, Food Chemical Codex and Taiwan FDA).

Chapter 5 features a detailed competitiveness analysis of the biopharmaceutical excipient manufacturers, based on supplier power (in terms of years of experience), company competitiveness (type of excipient based on chemical composition, function, chemical structure, and based on scale of operation, type of formulation, type of biologic, global regulatory compliance) and number of manufacturing facilities.

Chapter 6 provides detailed profiles of prominent players (shortlisted based on a proprietary criterion) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook. 

Chapter 7 features an analysis of the various collaborations and partnerships inked between stakeholders engaged in this domain, during the period 2016-2021, covering distribution agreements, acquisitions, supply agreements, product development agreements, asset acquisitions, research and development agreements, manufacturing agreements, service alliances and other related agreements.

Chapter 8 presents a detailed analysis of the recent expansions undertaken by various biopharmaceutical excipient manufacturers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, type of excipient, type of drug molecule, most active players (in terms of number of recent expansions) and geographical distribution (region-wise and country-wise).

Chapter 9 features a comprehensive analysis of the global installed capacity for biopharmaceutical excipients taking into consideration the capacities of various biopharmaceutical excipient manufacturers, along with information on the distribution of available global biopharmaceutical excipient production capacity based on several relevant parameters, such as company size (small, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial) and key geographical regions (North America, Europe, and Asia-Pacific).

Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of the biopharmaceutical excipient manufacturing market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of biologic (antibodies, vaccines, cell therapies and other biologics), [B] type of excipient (carbohydrates, polymers, solubilizers / surfactants, polyols, proteins / amino acids and others), [C] company size (small, mid-sized, large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).

Chapter 11 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 12 provides the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical excipient manufacturing domain. 

Chapter 13 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Biopharmaceutical Excipients
3.3. Properties of Ideal Excipients
3.4. Classification of Biopharmaceutical Excipients
3.4.1. Classification based on Route of Administration
3.4.2. Classification of Excipients based on Structure
3.4.3. Classification of Excipients based on Function
3.4.4. Classification based on Ability to Interfere with Metabolization and Efflux Mechanisms

3.5. Applications of Biopharmaceutical Excipients
3.6. Regulatory Scenario
3.7. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biopharmaceutical Excipient Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Biopharmaceutical Excipient Manufacturing Facilities
4.2.5. Analysis by Type of Excipient based on Chemical Composition
4.2.6. Analysis by Type of Excipient based on Function
4.2.7. Analysis by Type of Excipient based on Chemical Structure
4.2.8. Analysis by Scale of Operation
4.2.9. Analysis by Type of Formulation
4.2.10. Analysis by Type of Biologic
4.2.11. Analysis by Global Regulatory Compliance

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Biopharmaceutical Excipient Manufacturers: Company Competitiveness Analysis
5.4.1. Company Competitiveness Analysis: Small Companies
5.4.2. Company Competitiveness Analysis: Mid-Sized Companies
5.4.3. Company Competitiveness Analysis: Large Companies
5.4.4. Company Competitiveness Analysis: Very Large Companies

6. COMPANY PROFILES: BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS
6.1. Chapter Overview
6.2. ABITEC
6.2.1. Company Overview
6.2.2. Biopharmaceutical Excipient Offerings
6.2.3. Manufacturing Facilities
6.2.4. Recent Developments and Future Outlook

6.3. Avantor
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Biopharmaceutical Excipient Offerings
6.3.4. Manufacturing Facilities
6.3.5. Recent Developments and Future Outlook

6.4. BASF Pharma
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Biopharmaceutical Excipient Offerings
6.4.4. Manufacturing Facilities
6.4.5. Recent Developments and Future Outlook

6.5. Corden Pharma
6.5.1. Company Overview
6.5.2. Biopharmaceutical Excipient Service Offerings
6.5.3. Manufacturing Facilities
6.5.4. Recent Developments and Future Outlook

6.6. DFE Pharma
6.6.1. Company Overview
6.6.2. Biopharmaceutical Excipient Offerings
6.6.3. Manufacturing Facilities
6.6.4. Recent Developments and Future Outlook

6.7. Evonik
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Biopharmaceutical Excipient Offerings
6.7.4. Manufacturing Facilities
6.7.5. Recent Developments and Future Outlook

6.8. Kirsch Pharma
6.8.1. Company Overview
6.8.2. Biopharmaceutical Excipient Offerings
6.8.3. Manufacturing Facilities
6.8.4. Recent Developments and Future Outlook

6.9. Merck KGaA
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Biopharmaceutical Excipient Offerings
6.9.4. Manufacturing Facilities
6.9.5. Recent Developments and Future Outlook

6.10. Pfanstiehl
6.10.1. Company Overview
6.10.2. Biopharmaceutical Excipient Offerings
6.10.3. Manufacturing Facilities
6.10.4. Recent Developments and Future Outlook

6.11. Roquette
6.11.1. Company Overview
6.11.2. Biopharmaceutical Excipient Offerings
6.11.3. Manufacturing Facilities
6.11.4. Recent Developments and Future Outlook

6.12. Spectrum Chemical Manufacturing
6.12.1. Company Overview
6.12.2. Biopharmaceutical Excipient Offerings
6.12.3. Manufacturing Facilities
6.12.4. Recent Developments and Future Outlook

6.13. SPI Pharma
6.13.1. Company Overview
6.13.2. Biopharmaceutical Excipient Offerings
6.13.3. Manufacturing Facilities
6.13.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Biopharmaceutical Excipients Manufacturing Market: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Excipient
7.3.5. Analysis by Type of Drug Molecule
7.3.5. Most Active Players: Analysis by Number of Partnerships
7.3.6. Analysis by Geography
7.3.6.1. Intercontinental and Intracontinental Deals
7.3.6.2. International and Local Deals

8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Biopharmaceutical Excipient Manufacturing Market: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Company Size and Location of Headquarters
8.2.4. Analysis by Location of Expanded Facility
8.2.5. Analysis by Type of Excipient
8.2.6. Analysis by Type of Drug Molecule
8.2.7. Most Active Players: Analysis by Number of Recent Expansions
8.2.8. Geographical Analysis
8.2.8.1. Region-wise Distribution
8.2.8.2. Country-wise Distribution

9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Biopharmaceutical Excipient Manufacturing: Installed Global Capacity
9.3.1. Analysis by Company Size
9.3.2. Analysis by Scale of Operation
9.3.3. Analysis by Location of Manufacturing Facility
9.4. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Biopharmaceutical Excipient Manufacturing Market, 2022-2035
10.4. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035
10.5. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035
10.6. Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035
10.7. Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035
10.8. Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, 2022 and 2035
10.8.1. Biopharmaceutical Excipient Manufacturing Market in North America, 2022-2035
10.8.2. Biopharmaceutical Excipient Manufacturing Market in Europe, 2022-2035
10.8.3. Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, 2022-2035
10.8.4. Biopharmaceutical Excipient Manufacturing Market in Latin America, 2022-2035
10.8.5. Biopharmaceutical Excipient Manufacturing Market in MENA, 2022-2035
10.8.6. Biopharmaceutical Excipient Manufacturing Market in Rest of the World, 2022-2035

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. DFE Pharma
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Jeannette M. Wetzel, Biopharma Sales Director

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Forecast
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Recent Expansions
Figure 2.4 Executive Summary: Capacity Analysis
Figure 2.5 Executive Summary: Market Forecast
Figure 3.1 Properties of an Ideal Excipient
Figure 3.2 Classification of Biopharmaceutical Excipients based on Ability to Interfere with Metabolization and Efflux Mechanisms
Figure 3.3 Applications of Biopharmaceutical Excipients
Figure 4.1 Biopharmaceutical Excipient Manufacturers: Distribution by Year of Establishment
Figure 4.2 Biopharmaceutical Excipient Manufacturers: Distribution by Company Size
Figure 4.3 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters and Company Size
Figure 4.6 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Region-wise)
Figure 4.7 Biopharmaceutical Excipients Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Country-wise)
Figure 4.8 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Composition
Figure 4.9 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Function
Figure 4.10 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Structure
Figure 4.11 Biopharmaceutical Excipient Manufacturers: Distribution by Scale of Operation
Figure 4.12 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Formulation
Figure 4.13 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Biologic
Figure 4.14 Biopharmaceutical Excipient Manufacturers: Distribution by Global Regulatory Compliance
Figure 5.1 Company Competitiveness Analysis: Small Companies
Figure 5.2 Company Competitiveness Analysis: Mid-sized Companies
Figure 5.3 Company Competitiveness Analysis: Large Companies
Figure 5.4 Company Competitiveness Analysis: Very Large Companies
Figure 6.1 BASF Pharma: Annual Revenues, 2016-2021 (EUR Million)
Figure 6.2 Evonik: Annual Revenues, 2016-2020 (EUR Million)
Figure 6.3 Merck KGaA: Annual Revenues, 2016-2021 (EUR Million)
Figure 7.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2016-2021
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Excipient
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Drug Molecule
Figure 7.6 Partnerships and Collaborations: Year-Wise Trend of Partnerships by Type of Drug Molecule, 2016-2021
Figure 7.7 Most Active Players: Distribution by Number of Partnerships
Figure 7.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 7.9 Partnerships and Collaborations: International and Local Distribution
Figure 8.1 Recent Expansions: Cumulative Year-wise Trend, 2016-2021
Figure 8.2 Recent Expansions: Distribution by Type of Expansion
Figure 8.3 Recent Expansions: Distribution by Company Size and Location of Headquarters
Figure 8.4 Recent Expansions: Distribution by Location of Expanded Facility
Figure 8.5 Recent Expansions: Distribution by Location of Facility Expanded and Type of Expansion
Figure 8.6 Recent Expansions: Distribution by Type of Excipient
Figure 8.7 Recent Expansions: Distribution by Type of Drug Molecule
Figure 8.8 Most Active Players: Distribution by Number of Recent Expansions
Figure 8.9 Recent Expansions: Year-wise Distribution by Geography
Figure 8.10 Recent Expansions: Country-wise Distribution
Figure 9.1 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
Figure 9.2 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Company Size
Figure 9.3 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Figure 9.4 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Continent-wise)
Figure 9.5 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 10.1 Global Biopharmaceutical Excipient Manufacturing Market, 2022-2035 (USD Billion)
Figure 10.2 Biopharmaceutical Excipient Manufacturing Market: Likely Growth Scenarios
Figure 10.3 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035 (USD Billion)
Figure 10.4 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035 (USD Billion)
Figure 10.5 Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035 (USD Billion)
Figure 10.6 Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035 (USD Billion)
Figure 10.7 Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, 2022 and 2035(USD Billion)
Figure 10.8 Biopharmaceutical Excipient Manufacturing Market in North America, 2022-2035 (USD Billion)
Figure 10.9 Biopharmaceutical Excipient Manufacturing Market in Europe, 2022-2035 (USD Billion)
Figure 10.10 Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, 2022-2035 (USD Billion)
Figure 10.11 Biopharmaceutical Excipient Manufacturing Market in Latin America, 2022-2035 (USD Billion)
Figure 10.12 Biopharmaceutical Excipient Manufacturing Market in MENA, 2022-2035 (USD Billion)
Figure 10.13 Biopharmaceutical Excipient Manufacturing Market in Rest of the World, 2022-2035 (USD Billion)
Figure 11.1 Concluding Remarks: Overall Market Landscape
Figure 11.2 Concluding Remarks: Partnerships and Collaborations
Figure 11.3 Concluding Remarks: Recent Expansions
Figure 11.4 Concluding Remarks: Capacity Analysis
Figure 11.5 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Classification of Biopharmaceutical Excipients based on Function
Table 4.1 Biopharmaceutical Excipient Manufacturers: List of Companies
Table 4.2 Biopharmaceutical Excipient Manufacturers: Information on Type of Excipient based on Chemical Composition and Function
Table 4.3 Biopharmaceutical Excipient Manufacturers: Information on Scale of Operation, Type of Formulation, Type of Excipient (based on Chemical Structure), Type of Biologic and Global Regulatory Compliance
Table 6.1 Leading Biopharmaceutical Excipient Manufacturers
Table 6.2 ABITEC: Company Snapshot
Table 6.3 ABITEC: Biopharmaceutical Excipient Offerings
Table 6.4 ABITEC: Information on Manufacturing Facilities
Table 6.5 ABITEC: Recent Developments and Future Outlook
Table 6.6 Avantor: Company Snapshot
Table 6.7 Avantor: Biopharmaceutical Excipient Offerings
Table 6.8 Avantor: Information on Manufacturing Facilities
Table 6.9 Avantor: Recent Developments and Future Outlook
Table 6.10 BASF: Company Snapshot
Table 6.11 BASF: Biopharmaceutical Excipient Offerings
Table 6.12 BASF: Information on Manufacturing Facilities
Table 6.13 BASF: Recent Developments and Future Outlook
Table 6.14 Corden Pharma: Company Snapshot
Table 6.15 Corden Pharma: Biopharmaceutical Excipient Offerings
Table 6.16 Corden Pharma: Information on Manufacturing Facilities
Table 6.17 Corden Pharma: Recent Developments and Future Outlook
Table 6.18 DFE Pharma: Company Snapshot
Table 6.19 DFE Pharma: Biopharmaceutical Excipient Offerings
Table 6.20 DFE Pharma: Information on Manufacturing Facilities
Table 6.21 DFE Pharma: Recent Developments and Future Outlook
Table 6.22 Evonik: Company Snapshot
Table 6.23 Evonik: Biopharmaceutical Excipient Offerings
Table 6.24 Evonik: Information on Manufacturing Facilities
Table 6.25 Evonik: Recent Developments and Future Outlook
Table 6.26 Kirsch Pharma: Company Snapshot
Table 6.27 Kirsch Pharma: Biopharmaceutical Excipient Offerings
Table 6.28 Kirsch Pharma: Information on Manufacturing Facilities
Table 6.29 Kirsch Pharma: Recent Developments and Future Outlook
Table 6.30 Merck KGaA: Company Snapshot
Table 6.31 Merck KGaA: Biopharmaceutical Excipient Offerings
Table 6.32 Merck KGaA: Information on Manufacturing Facilities
Table 6.33 Merck KGaA: Recent Developments and Future Outlook
Table 6.34 Pfanstiehl: Company Snapshot
Table 6.35 Pfanstiehl: Biopharmaceutical Excipient Offerings
Table 6.36 Pfanstiehl: Information on Manufacturing Facilities
Table 6.37 Pfanstiehl: Recent Developments and Future Outlook
Table 6.38 Roquette: Company Snapshot
Table 6.39 Roquette: Biopharmaceutical Excipient Offerings
Table 6.40 Roquette: Information on Manufacturing Facilities
Table 6.41 Roquette: Recent Developments and Future Outlook
Table 6.42 Spectrum Chemical Manufacturing: Company Snapshot
Table 6.43 Spectrum Chemical Manufacturing: Biopharmaceutical Excipient Offerings
Table 6.44 Spectrum Chemical Manufacturing: Information on Manufacturing Facilities
Table 6.45 SPI Pharma: Company Snapshot
Table 6.46 SPI Pharma: Biopharmaceutical Excipient Offerings
Table 6.47 SPI Pharma: Information on Manufacturing Facilities
Table 6.48 SPI Pharma: Recent Developments and Future Outlook
Table 7.1 Biopharmaceutical Excipient Manufacturers: List of Partnerships and Collaborations, 2016-2021
Table 8.1 Biopharmaceutical Excipient Manufacturers: Recent Expansions, 2016-2021
Table 9.1 Capacity Analysis: Information on Company Size of Biopharmaceutical Excipient Manufacturers
Table 9.2 Capacity Analysis: Information on Average Capacity by Company Size
Table 9.3 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Total Capacity by Company Size
Table 12.1 DFE Pharma: Company Snapshot
Table 13.1 Biopharmaceutical Excipient Manufacturers: Distribution by Year of Establishment
Table 13.2 Biopharmaceutical Excipient Manufacturers: Distribution by Company Size
Table 13.3 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Region-wise)
Table 13.4 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 13.5 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters and Company Size
Table 13.6 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Region-wise)
Table 13.7 Biopharmaceutical Excipients Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Country-wise)
Table 13.8 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Composition
Table 13.9 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Function
Table 13.10 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Structure
Table 13.11 Biopharmaceutical Excipient Manufacturers: Distribution by Scale of Operation
Table 13.12 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Formulation
Table 13.13 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Biologic
Table 13.14 Biopharmaceutical Excipient Manufacturers: Distribution by Global Regulatory Compliance
Table 13.15 BASF Pharma: Annual Revenues, 2016-2021 (EUR Million)
Table 13.16 Evonik: Annual Revenues, 2016-2020 (EUR Million)
Table 13.17 Merck KGaA: Annual Revenues, 2016-2021 (EUR Million)
Table 13.18 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2016-2021
Table 13.19 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.20 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 13.21 Partnerships and Collaborations: Distribution by Type of Excipient
Table 13.22 Partnerships and Collaborations: Distribution by Type of Drug Molecule
Table 13.23 Partnerships and Collaborations: Year-Wise Trend of Partnerships by Type of Drug Molecule, 2016-2021
Table 13.24 Most Active Players: Distribution by Number of Partnerships
Table 13.25 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Deals
Table 13.26 Partnerships and Collaborations: Distribution by International and Local Deals
Table 13.27 Recent Expansions: Cumulative Year-wise Trend, 2016-2021
Table 13.28 Recent Expansions: Distribution by Type of Expansion
Table 13.29 Recent Expansions: Distribution by Company Size and Location of Headquarters
Table 13.30 Recent Expansions: Distribution by Location of Expanded Facility
Table 13.31 Recent Expansions: Distribution by Location of Facility Expanded and Type of Expansion
Table 13.32 Recent Expansions: Distribution by Type of Excipient
Table 13.33 Recent Expansions: Distribution by Type of Drug Molecule
Table 13.34 Most Active Players: Distribution by Number of Recent Expansions
Table 13.35 Recent Expansions: Year-wise Distribution by Geography
Table 13.36 Recent Expansions: Country-wise Distribution
Table 13.37 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
Table 13.38 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Company Size
Table 13.39 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Table 13.40 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Continent-wise)
Table 13.41 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Country-wise)
Table 13.42 Global Biopharmaceutical Excipient Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.43 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035 (USD Billion)
Table 13.44 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035 (USD Billion)
Table 13.45 Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035 (USD Billion)
Table 13.46 Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035 (USD Billion)
Table 13.47 Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, Conservative, Base and Optimistic Scenarios, 2022 and 2035 (USD Billion)
Table 13.48 Biopharmaceutical Excipient Manufacturing Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.49 Biopharmaceutical Excipient Manufacturing Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.50 Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.51 Biopharmaceutical Excipient Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.52 Biopharmaceutical Excipient Manufacturing Market in MENA, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.53 Biopharmaceutical Excipient Manufacturing Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. A&C
  2. ABITEC
  3. Aceto
  4. Aditya Chemicals
  5. Alfa Aesar
  6. AMCM
  7. AmpTec
  8. ANGUS Chemical Company
  9. Apothecon Pharmaceuticals
  10. Asahi Kasei
  11. Avanti Polar Lipids
  12. Avantor
  13. Azelis Americas
  14. Barentz
  15. BASF 
  16. BioNTech
  17. BioSpectra
  18. BOC Sciences
  19. Brenntag
  20. Cascade Chemistry 
  21. CG Chemikalien
  22. Cole-Parmer
  23. CordenPharma
  24. CPI
  25. Creative Biostructure
  26. Crest Cellulose (Acquired by Roquette)
  27. Croda
  28. DFE Pharma
  29. DKSH
  30. DuPont
  31. DURECT
  32. Evonik
  33. Finar
  34. GELITA
  35. Harro Höfliger Verpackungsmaschinen
  36. Hawkins
  37. Hopax Fine Chemicals
  38. Hosokawa Micron Powder Systems
  39. Hunan Er-Kang Pharmaceutical
  40. IMCD
  41. IMCoPharma
  42. Indchem International 
  43. InnoCore Pharmaceuticals
  44. International Flavors & Fragrances 
  45. InVitria
  46. Itacel (Acquired by Roquette)
  47. ITW Reagents (A division of PanReac AppliChem)
  48. Kerry
  49. Kirsch Pharma
  50. Kuraray
  51. Larodan
  52. Lazuline Biotech
  53. LeBaronBrown Specialities
  54. LUCA AICell
  55. MaaS Pharma Chemicals
  56. MEGGLE
  57. Merck KGaA
  58. Mitushi Biopharma
  59. Moderna
  60. National Institute of Bioprocessing Research and Training
  61. Nordmann, Rassmann
  62. PCAS
  63. Pfanstiehl
  64. Pfizer
  65. Quadra Chemicals
  66. ReForm Biologics
  67. Roquette
  68. Shanghai Huamao Pharmaceutical 
  69. Sigachi
  70. Spectrum Chemical Mfg.
  71. SPI Pharma
  72. Stanford University
  73. TTY Biopharm
  74. Univar Solutions
  75. VAV Life Sciences
  76. Wilshire Technologies

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com